glutathione injection for glowing skin Whitening: Cost, Benefits And Side Effects Skin Brightening & Glow with

Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Links CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 title claims abstract description 64 UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 title claims abstract description 60 RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 56 239000000203 mixture Substances 0.000 title claims abstract description 36 229910000029 sodium carbonate Inorganic materials 0.000 title claims abstract description 32 229910000030 sodium bicarbonate Inorganic materials 0.000 title claims abstract description 30 235000017557 sodium bicarbonate Nutrition 0.000 title claims abstract description 30 108010024636 Glutathione Proteins 0.000 title abstract description 7 229960003180 glutathione Drugs 0.000 claims description 48 235000003969 glutathione Nutrition 0.000 claims description 48 239000000843 powder Substances 0.000 claims description 34 238000005303 weighing Methods 0.000 claims description 17 235000017550 sodium carbonate Nutrition 0.000 claims description 14 238000000034 method Methods 0.000 claims description 7 230000003115 biocidal effect Effects 0.000 claims description 3 239000002994 raw material Substances 0.000 claims description 2 230000001954 sterilising effect Effects 0.000 claims description 2 238000004659 sterilization and disinfection Methods 0.000 claims description 2 238000004519 manufacturing process Methods 0.000 abstract description 8 230000008901 benefit Effects 0.000 abstract description 5 238000005265 energy consumption Methods 0.000 abstract description 4 UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract description 3 239000003814 drug Substances 0.000 abstract description 2 229940079593 drug Drugs 0.000 abstract 1 238000010999 medical injection Methods 0.000 abstract 1 238000012856 packing Methods 0.000 description 16 238000005516 engineering process Methods 0.000 description 12 238000004108 freeze drying Methods 0.000 description 12 KJQNSWHBRKOGHW-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;sodium Chemical compound [Na].OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O KJQNSWHBRKOGHW-GEMLJDPKSA-N 0.000 description 4 DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4 238000002512 chemotherapy Methods 0.000 description 3 230000000694 effects Effects 0.000 description 3 230000004060 metabolic process Effects 0.000 description 3 238000012360 testing method Methods 0.000 description 3 CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2 239000004471 Glycine Substances 0.000 description 2 QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2 210000004027 cell Anatomy 0.000 description 2 230000008859 change Effects 0.000 description 2 238000001035 drying Methods 0.000 description 2 238000011835 investigation Methods 0.000 description 2 230000003647 oxidation Effects 0.000 description 2 238000007254 oxidation reaction Methods 0.000 description 2 229910052760 oxygen Inorganic materials 0.000 description 2 239000001301 oxygen Substances 0.000 description 2 238000002360 preparation method Methods 0.000 description 2 150000003254 radicals Chemical class 0.000 description 2 238000001959 radiotherapy Methods 0.000 description 2 WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1 BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1 239000004380 Cholic acid Substances 0.000 description 1 101710088194 Dehydrogenase Proteins 0.000 description 1 208000004232 Enteritis Diseases 0.000 description 1 102000004190 Enzymes Human genes 0.000 description 1 108090000790 Enzymes Proteins 0.000 description 1 208000004930 Fatty Liver Diseases 0.000 description 1 WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1 206010019708 Hepatic steatosis Diseases 0.000 description 1 206010019799 Hepatitis viral Diseases 0.000 description 1 206010021143 Hypoxia Diseases 0.000 description 1 206010061218 Inflammation Diseases 0.000 description 1 XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1 WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1 206010028980 Neoplasm Diseases 0.000 description 1 238000010521 absorption reaction Methods 0.000 description 1 239000002253 acid Substances 0.000 description 1 208000007502 anemia Diseases 0.000 description 1 230000003078 antioxidant effect Effects 0.000 description 1 230000008827 biological function Effects 0.000 description 1 230000023852 carbohydrate metabolic process Effects 0.000 description 1 235000021256 carbohydrate metabolism Nutrition 0.000 description 1 229910052799 carbon Inorganic materials 0.000 description 1 239000001569 carbon dioxide Substances 0.000 description 1 229910002092 carbon dioxide Inorganic materials 0.000 description 1 238000006243 chemical reaction Methods 0.000 description 1 BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1 229960002471 cholic acid Drugs 0.000 description 1 235000019416 cholic acid Nutrition 0.000 description 1 230000001684 chronic effect Effects 0.000 description 1 208000019425 cirrhosis of liver Diseases 0.000 description 1 239000005515 coenzyme Substances 0.000 description 1 XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1 235000018417 cysteine Nutrition 0.000 description 1 230000006378 damage Effects 0.000 description 1 230000009849 deactivation Effects 0.000 description 1 KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1 239000002552 dosage form Substances 0.000 description 1 238000002474 experimental method Methods 0.000 description 1 208000010706 fatty liver disease Diseases 0.000 description 1 230000006870 function Effects 0.000 description 1 210000001035 gastrointestinal tract Anatomy 0.000 description 1 235000013922 glutamic acid Nutrition 0.000 description 1 239000004220 glutamic acid Substances 0.000 description 1 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1 239000005556 hormone Substances 0.000 description 1 229940088597 hormone Drugs 0.000 description 1 210000005260 human cell Anatomy 0.000 description 1 208000018875 hypoxemia Diseases 0.000 description 1 239000012535 impurity Substances 0.000 description 1 230000004054 inflammatory process Effects 0.000 description 1 238000002347 injection Methods 0.000 description 1 239000007924 injection Substances 0.000 description 1 238000010255 intramuscular injection Methods 0.000 description 1 239000007927 intramuscular injection Substances 0.000 description 1 238000001990 intravenous administration Methods 0.000 description 1 238000010253 intravenous injection Methods 0.000 description 1 230000003902 lesion Effects 0.000 description 1 239000007788 liquid Substances 0.000 description 1 210000004185 liver Anatomy 0.000 description 1 230000007774 longterm Effects 0.000 description 1 230000002503 metabolic effect Effects 0.000 description 1 239000011812 mixed powder Substances 0.000 description 1 210000000056 organ Anatomy 0.000 description 1 231100000572 poisoning Toxicity 0.000 description 1 230000000607 poisoning effect Effects 0.000 description 1 230000010181 polygamy Effects 0.000 description 1 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1 108090000765 processed proteins & peptides Proteins 0.000 description 1 230000005855 radiation Effects 0.000 description 1 230000008439 repair process Effects 0.000 description 1 229910052708 sodium Inorganic materials 0.000 description 1 239000011734 sodium Substances 0.000 description 1 239000000243 solution Substances 0.000 description 1 238000013112 stability test Methods 0.000 description 1 231100000240 steatosis hepatitis Toxicity 0.000 description 1 230000001225 therapeutic effect Effects 0.000 description 1 208000037816 tissue injury Diseases 0.000 description 1 231100000331 toxic Toxicity 0.000 description 1 230000002588 toxic effect Effects 0.000 description 1 230000004102 tricarboxylic acid cycle Effects 0.000 description 1 150000003641 trioses Chemical class 0.000 description 1 201000001862 viral hepatitis Diseases 0.000 description 1 239000011782 vitamin Substances 0.000 description 1 229940088594 vitamin Drugs 0.000 description 1 229930003231 vitamin Natural products 0.000 description 1 235000013343 vitamin Nutrition 0.000 description 1 150000003722 vitamin derivatives Chemical class 0.000 description 1 Landscapes Medicinal Preparation (AREA) Abstract The invention relates to a composition of reduced glutathione and sodium carbonate or sodium bicarbonate, which is used for medical injection drugs

Future research should further optimize the biocompatibility and scalable manufacturing processes of nanocarriers

In Phase 2, glutathione steps in

& Pietrobon, D

Insulin-like growth factor-I regulation of luteinizing hormone (LH) receptor messenger ribonucleic acid expression and LH-stimulated signal transduction in rat ovarian theca-interstitial cells